Bosslet K, Czech J, Lorenz P, Sedlacek H H, Schuermann M, Seemann G
Research Laboratory of Behringwerke, Marburg, Germany.
Br J Cancer. 1992 Feb;65(2):234-8. doi: 10.1038/bjc.1992.47.
A fusion protein consisting of the humanised Fab fragment of the anti CEA MAb BW 431 and the human beta-glucuronidase was expressed in BHK cells. Functional testing revealed that the specificity and avidity of the humanised V region was similar to the original murine MAb BW 431. Furthermore, the enzymatic activity, pH sensitivity and stability of the human beta-glucuronidase in the fusion protein was comparable to the activity of recombinant human beta-glucuronidase. Using anti-idiotype affinity chromatography, two molecules of a molecular weight of 125 kDa or 250 kDa could be visualized under nonreducing conditions in SDS-PAGE. Reducing conditions revealed a 25 kDa light and 100 kDa heavy chain. Due to its suitable biological characteristics this fusion protein might be an appropriate molecule allowing a site specific antibody directed enzyme prodrug therapy (ADEPT) in vivo.
一种由抗癌胚抗原单克隆抗体BW 431的人源化Fab片段与人类β-葡萄糖醛酸酶组成的融合蛋白在BHK细胞中表达。功能测试表明,人源化V区的特异性和亲和力与原始鼠源单克隆抗体BW 431相似。此外,融合蛋白中人类β-葡萄糖醛酸酶的酶活性、pH敏感性和稳定性与重组人β-葡萄糖醛酸酶的活性相当。使用抗独特型亲和层析法,在SDS-PAGE的非还原条件下可以看到分子量为125 kDa或250 kDa的两个分子。还原条件下显示出一条25 kDa的轻链和一条100 kDa的重链。由于其合适的生物学特性,这种融合蛋白可能是一种合适的分子,能够在体内实现位点特异性抗体导向酶前药疗法(ADEPT)。